BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Doxorubicin, rs7903146, NEUROG3, Apoptosis, Obesity, Adipose tissue, Pharmacogenetics)
Bookmark Forward

QuickView for MYC (gene)


Body Atlas

Most Correlated Tissues

  1. B lymphocyte (IgM memory) of spleen
  2. Vena cava
  3. Granulocyte-macrophage progenitor cell of bone marrow
  4. B lymphocyte (naive) of spleen
  5. Omental adipose tissue
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Hyperoxia
  2. B-cell lymphoma
  3. Whipple's disease
  4. Physical activity
  5. Irritable bowel syndrome
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. CEP 14083
  2. microcystin RR
  3. FGF10 protein, human
  4. Quinacrine
  5. CGP 60474
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. Bcl6
  2. MIR141
  3. PRKDC
  4. PRKAR1B
  5. MAP2K7
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Survey of activation-induced genome architecture reveals a novel enhancer of Myc.
  2. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target i…
  3. MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding site…
  4. Therapeutic targeting of "undruggable" MYC.
  5. Development and Characterization of Benzoselenazole Derivatives as Potent and Selective c-MYC Transc…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Dose-adjusted EPOCH-R in MYC Positive DLBCL
  2. Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
  3. Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myelo…
  4. Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients …
  5. BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
Explore Clinical Trials Results
  • Copyright © 2023 Illumina Inc. All rights reserved.